Lung cancer – Erlotinib
Reports looking at Erlotinib for the treatment of non-small cell lung cancer and the risk and costs of febrile neutropenia in patients with non-small cell lung cancer treated with docetaxel.
NICE appraisal
TA162 Erlotinib for the treatment of non-small cell lung cancer (PDF, 29KB) (November 2008)
DSU reports
The risk and costs of febrile neutropenia in patients with non-small cell lung cancer treated with docetaxel (PDF, 158KB) (December 2007)
Related publications
A Wailoo, A Sutton, A Morgan, The risk of febrile neutropenia in patients with non-small cell lung cancer treated with Docetaxel: a systematic review and meta-analysis 2009 British Journal of Cancer Vol 100: 436-441